Please assess the completion status of the following clinical trial:

Trial Title: Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged 14 years or older.~* One of the following with documentation of culture positive or molecular test within 3 months of screening:~  * XDR-TB defined as resistance to rifamycins, a fluoroquinolone AND an injectable OR~ * Pre-XDR-TB with defined as resistance to rifamycins, and to a fluoroquinolone OR an injectable OR~ * MDR-TB with resistance to rifamycins, and either non-responsive or non-tolerant to current treatment.~* Of non-childbearing potential or willing to practice effective birth control methods.~* Complete informed consent form.~Exclusion criteria:~* Karnofsky score \< 60 at screening.~* Body mass index (BMI) \< 17 kg/m2~* Participants who are expected to require a surgical procedure (for Pulmonary TB).~* Any risk factor for QT prolongation~* Pregnant or breast-feeding~* Any planned contraindicated medicines or received more than 2 weeks of bedaquiline, linezolid or delamanid prior to first dose of IMP.~* A peripheral neuropathy of Grade 3 or 4, according to DMID. Or, participants with a Grade 1 or 2 neuropathy which is likely to progress/worsen over the course of the study, in the opinion of the Investigator~* Any of the following lab toxicities/abnormalities:~  * Viral load \>1000 copies/mL (Unless newly diagnosed HIV and not yet on ART who otherwise qualify for participation);~ * CD4+ count \< 100 cells/µL (HIV positive participants);~ * Serum potassium less than the lower limit of normal for the laboratory;~ * Hemoglobin \< 9.0 g/dL or 90g/L;~ * Platelets \<100,000/mm3 or \< 100 x 10\^9/L~ * Absolute neutrophil count (ANC) \< 1500/ mm3 or \< 1.5 x 10\^9/L~ * Aspartate aminotransferase (AST) and Alanini aminotransferase (ALT) Grade 3 or greater (\> 3.0 x ULN)~ * Total bilirubin greater than 1.5 x ULN~ * Direct bilirubin greater than ULN~ * Serum creatinine level greater than 1.5 times upper limit of normal~ * Albumin \<3.0 g/dl or \< 30 g/L

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1200mg L x 26 weeks + Pa + B (Type: EXPERIMENTAL): 2 linezolid 600 mg active tablets once daily for 26 weeks plus 1 placebo linezolid 300 mg half tablet once daily for 26 weeks plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
- 1200 mg L x 9 weeks + Pa + B (Type: EXPERIMENTAL): 2 linezolid 600 mg active tablets once daily for 9 weeks, 1 placebo linezolid 300 mg half tablet once daily for 9 weeks (for Weeks 1-9); 2 placebo linezolid 600 mg tablets once daily for 17 weeks, 1 placebo linezolid 300 mg half tablet once daily for 17 weeks (for Weeks 10-26) plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
- 600 mg L x 26 weeks + Pa + B (Type: EXPERIMENTAL): 1 linezolid 600 mg active tablet once daily for 26 weeks, 1 placebo linezolid 600 mg tablet once daily for 26 weeks, 1 placebo linezolid 300 mg half tablet once daily for 26 weeks plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
- 600 mg L x 9 weeks + Pa + B (Type: EXPERIMENTAL): 1 linezolid 600 mg active tablets once daily for 8 weeks, 1 placebo linezolid 600 mg half tablet once daily for 9 weeks, 1 placebo linezolid 300 mg half tablet once daily for 9 weeks (for Weeks 1-9); 2 placebo linezolid 600 mg tablets once daily for 17 weeks, 1 placebo linezolid 300 mg half tablet once daily for 17 weeks (for Weeks 10-26) plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete